Article
Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma.
European journal of cancer (Oxford, England : 1990) - 1 May 2024
Cao Hang, Ma Zelin, Huang Qingyuan, Han Han, Li Yuan, Zhang Yang, Chen Haiquan
Abstract excerpt
BACKGROUND: In light of the ongoing clinical development of KRAS G12D-specific inhibitors, we sought to investigate the clinicopathologic, co-occurring genomic features and outcomes of patients with KRAS G12D-mutant lung adenocarcinoma. METHODS: 3828 patients with completely resected primary lung adenocarcinomas were examined for KRAS mutations between 2008 and 2020. The association between KRAS G12D and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.